Fengxiang (9977 HK): PAG Invites Dissent After Scrapping Scrip Alternative
In an unusual move, the Offeror, PAG, and 59.42% shareholder of Shandong Fengxiang (9977 HK), has opted not to provide a scrip alternative, despite satisfying conditions to do so.
The scrip option condition - not less than 0.5% of shares out expressing interest - was satisfied on the 12th May. Therefore at least 7.9mn shares got snubbed.
Evidently PAG reckons the support for the scrip is not worth the trouble. Nor critical in mass to disrupt the Offer.
Fengxiang is super illiquid - look away now if this is not your thing.
The Trade:
This still looks done.
Pricing appears fair.
However this is an illiquid arb - and Hong Kong has seen two failed small-cap Schemes recently.
If illiquid arbs are your bent, and assuming completion late August, I'd pay up to HK$1.90/share.
The NEW News
The scrip alternative arrangement (mostly) mirrored that seen in L'Occitane (973 HK)'s and Shanghai Henlius Biotech (2696 HK)'s playbooks (see L'Occitane (973 HK): No, PLP Is Not Getting A Back-End Bump and Henlius Biotech (2696 HK): Fosun Pharma's "Fair" Offer)
This option, into "Rollover Securities", which was at "the sole discretion of the Offeror" was predicated on 0.5% of shares out (7.916mn shares) notifying the Offeror, in writing, expressing an interest in the scrip alternative.
Such notification must be received by the 11th May.
That was subsequently satisfied. The quantum of those seeking scrip was not made public.
Maximum scrip issuance? Rollover shares shall not exceed 5% of shares out or 79.167mn shares.
As seen below, independent comprise 218.5mn shares.
This scrip alternative is being offered to all shareholders except Falcon (the Offeror) and Platinum Peony (Abu Dhabi Investment Authority).
After the close yesterday, after careful consideration, the Offeror "decided not to introduce the Potential Share Alternative Offer."
No reason was given. Presumably the scrip interest was only at, or a little more than 0.5%.
So that's that.
Keep reading with a 7-day free trial
Subscribe to Hong Kong/China M&A/Events to keep reading this post and get 7 days of free access to the full post archives.